Global Intellectual Property, International Trade, and Legislative Developments
9:00 AM – 9:55 AM The Current International Intellectual Property Legislative Landscape
• Updates on EU Commission Issues
o EU Standard Essential Patent (SEP) Proposals
o EU Pharma Package Insights
• Potential impact of the 2024 European Parliament election in Germany
• Antisuit injunctions
10:00 AM – 10:55 AM Insights & Updates from the Unified Patent Court (UPC)
• Exploration of Key Decisions and Emerging Patterns
• Considerations Regarding Injunctions and Securities
• Accessibility of Documents and Transparency
11:00 AM – 11:55 AM Artificial Intelligence (AI), Copyright, and Data Privacy
• Global Trends and Recent Rulings
• Regulatory Oversight Implications
• PTO guidance on patents and AI inventorship
• Incorporation of AI in Courtroom Proceedings
12:00 PM – 12:55 PM Lunch Break
1:00 PM – 1:55 PM Current State of International Trade
• The treatment of confidential and other information is going through transition. The CIT recently issued a decision on BPI information in an ITC case. The Federal Circuit issued its decision in Royal Brush about the agency’s authority to issue protective orders. The Federal Circuit has also recently changed its court rules about using confidential information in briefs. The panel will discuss these recent events through the lens of trade and customs practice in the CIT and Federal Circuit.
2:00 PM – 2:55 PM The Current U.S. Intellectual Property Legislative Landscape
• U.S. Congressional Staff Perspectives
• Potential IP and Trade Implications of the 2024 U.S. Presidential Election
2:55 PM – 3:10 PM Networking Break
3:10 PM – 4:05 PM Global Litigation Insights
• Litigation Funding
o Examining the Implications on National Security in External Funding Sources
o Comparative Analysis of Jurisdiction-specific Approaches
o Ethical Considerations in Litigation Funding
• 1782 Petitions / discovery
• Remedies
• Unified v Bifurcated systems
4:10 PM – 5:05 PM Life Sciences and Pharma Considerations
• The pricing of pharmaceuticals in the context of intellectual property and innovation remains a global discussion and debate. This panel will take up recent issues related to such discussion and debate, including unpacking Bayh-Dole and march-in rights, evaluating the impact of the Inflation Reduction Act, and reviewing the status of compulsory licensing.
5:05 PM – 6:30 PM Networking Reception
Individual Registration Pricing:
FCBA Members: $200
FCBA Government/Educator Members: $50
Non-members: $400
Government/Educator Non-members: $100
As is typical of Global Series sessions, CLE will not be applied for by the Association.